Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, "Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions."
“New patent coverage for these cefazolin and ceftriaxone groups broadens our CNS-related portfolio and strengthens our intellectual property position as well.”
The patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive disorders. It also covers several novel compounds.
Rick Soni, President of Rexahn, noted, "New patent coverage for these cefazolin and ceftriaxone groups broadens our CNS-related portfolio and strengthens our intellectual property position as well."
Combination therapy shows promising results in treating stage 3 melanoma